Clinical data | |
---|---|
Other names | N-carbamoyl-5-methyl-2-oxo-3-prop-2-enyloxolane-3-carboxamide |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.019.871 |
Chemical and physical data | |
Formula | C10H14N2O4 |
Molar mass | 226.232 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Valofane is a sedative drug structurally related to the barbiturates and similar drugs such as primidone. It is metabolized once inside the body to form the barbiturate proxibarbital (proxibarbal) and is thus a prodrug.
References
- Traversa U, Puppini P, Jacquot C, Vertua R (1985). "Effect of an atypical barbiturate, the 2-allophanyl-2-allyl-4-valerolactone (valofan), on exploratory behaviour and brain serotonin concentrations in mice". Journal de Pharmacologie. 16 (3): 279–90. PMID 2415778.
- Lambrey B, Compagnon PL, Jacquot C (1981). "Pharmacokinetics of 14C-2-allophanyl-2-allyl -gamma-valero-lactone: a prodrug of proxibarbal in rats". European Journal of Drug Metabolism and Pharmacokinetics. 6 (3): 161–9. doi:10.1007/BF03189485. PMID 6118275. S2CID 10197120.
GABAA receptor positive modulators | |
---|---|
Alcohols | |
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This sedative-related article is a stub. You can help Misplaced Pages by expanding it. |